Pfizer: Beqvez Gene Therapy Decreases Bleeding Rates in Hemophilia B Patients

Hemophilia B patients given Beqvez had a decreased incidence of total bleeding Beqvez reduced the use of routine factor IX infusions The Latest A recent Phase III open-label, single-arm study conducted by Pfizer in collaboration with Spark Therapeutics investigated the safety and efficacy of a gene therapy named Beqvez in adult male patients with moderately

Related Keywords

New York , United States , American , , Minute Medicine Inc , World Federation Of Hemophilia , Pfizer , Company History , Spark Therapeutics , World Federation ,